Literature DB >> 15767426

Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2.

Grant A Darnell1, Toni M Antalis, Barbara R Rose, Andreas Suhrbier.   

Abstract

The serine protease inhibitor SerpinB2 (PAI-2), a major product of differentiating squamous epithelial cells, has recently been shown to bind and protect the retinoblastoma protein (Rb) from degradation. In human papillomavirus type 18 (HPV-18)-transformed epithelial cells the expression of the E6 and E7 oncoproteins is controlled by the HPV-18 upstream regulatory region (URR). Here we illustrate that PAI-2 expression in the HPV-18-transformed cervical carcinoma line HeLa resulted in the restoration of Rb expression, which led to the functional silencing of transcription from the HPV-18 URR. This caused loss of E7 protein expression and restoration of multiple E6- and E7-targeted host proteins, including p53, c-Myc, and c-Jun. Rb expression emerged as sufficient for the transcriptional repression of the URR, with repression mediated via the C/EBPbeta-YY1 binding site (URR 7709 to 7719). In contrast to HeLa cells, where the C/EBPbeta-YY1 dimer binds this site, in PAI-2- and/or Rb-expressing cells the site was occupied by the dominant-negative C/EBPbeta isoform liver-enriched transcriptional inhibitory protein (LIP). PAI-2 expression thus has a potent suppressive effect on HPV-18 oncogene transcription mediated by Rb and LIP, a finding with potential implications for prognosis and treatment of HPV-transformed lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767426      PMCID: PMC1061571          DOI: 10.1128/JVI.79.7.4246-4256.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

Review 1.  The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature.

Authors:  G A Silverman; P I Bird; R W Carrell; F C Church; P B Coughlin; P G Gettins; J A Irving; D A Lomas; C J Luke; R W Moyer; P A Pemberton; E Remold-O'Donnell; G S Salvesen; J Travis; J C Whisstock
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

2.  Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2).

Authors:  B C Risse; H Brown; R M Lavker; J M Pearson; M S Baker; D Ginsburg; P J Jensen
Journal:  Histochem Cell Biol       Date:  1998-12       Impact factor: 4.304

3.  Novel binding sites for regulatory factors in the human papillomavirus type 18 enhancer and promoter identified by in vivo footprinting.

Authors:  P H Bednarek; B J Lee; S Gandhi; E Lee; B Phillips
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer.

Authors:  C A Zahnow; P Younes; R Laucirica; J M Rosen
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

5.  Overexpression of C/EBPbeta represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein.

Authors:  T Bauknecht; Y Shi
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.

Authors:  A Daneri-Navarro; G Macias-Lopez; A Oceguera-Villanueva; S Del Toro-Arreola; A Bravo-Cuellar; R Perez-Montfort; S Orbach-Arbouys
Journal:  Eur J Cancer       Date:  1998-03       Impact factor: 9.162

7.  Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity.

Authors:  B Rose; G Steger; X P Dong; C Thompson; Y Cossart; M Tattersall; H Pfister
Journal:  J Gen Virol       Date:  1998-07       Impact factor: 3.891

8.  TCDD-inducible plasminogen activator inhibitor type 2 (PAI-2) in human hepatocytes, HepG2 and monocytic U937 cells.

Authors:  G Gohl; T Lehmköster; P A Münzel; D Schrenk; R Viebahn; K W Bock
Journal:  Carcinogenesis       Date:  1996-03       Impact factor: 4.944

9.  The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming.

Authors:  T M Antalis; M La Linn; K Donnan; L Mateo; J Gardner; J L Dickinson; K Buttigieg; A Suhrbier
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

10.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.

Authors:  H Yoshino; Y Endo; Y Watanabe; T Sasaki
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.